Pain is the principal clinical symptom of osteoarthritis (OA), and development of safe and effective analgesics for OA pain is needed. Drug development of new analgesics for OA pain is impaired by substantial change in pain in patients receiving placebo, and more data describing clinical characteristics and pain categories particularly associated with this phenomenon is needed.
The purpose of this post-hoc analysis was to investigate clinical characteristics and pain categories and their association with radiographic progression and placebo pain reduction (PPR) in OA patients as measured the Western Ontario and McMasters Arthritis (WOMAC).
Pooled data from the placebo groups of two phase III randomized clinical trials in patients with knee OA followed for 2 years were analyzed. Differences between individual sub-scores and pain categories of weight-bearing and non-weight bearing pain over time were assessed. Selected patient baseline characteristics were assessed for association with PPR. Association between pain categories and radiographic progression was analyzed.
The reduction of pain in placebo-treated patients was significantly higher in the composite of questions related to weight-bearing pain compared to non-weight-bearing pain of the target knee. Baseline BMI, age and JSW were not associated with pain change. Pain reduction was higher in the Target knee, compared to the Non-Target knee at all corresponding time-points. A very weak correlation was found between weight-bearing pain and progression in the non-target knee.
These results indicate that the reduction in pain in patients treated with placebo is significantly different between pain categories, as weight-bearing pain was significantly more reduced compared to non-weight-bearing pain. Further research in pain categories in OA is warranted.
TE MA, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis. Cartilage. 2014;22:363–88.
rendt-Nielsen L, Eskehave TN, Egsgaard LL, Petersen KK, Graven-Nielsen T, Hoeck HC, et al. Association between experimental pain biomarkers and serologic markers in patients with different degrees of painful knee osteoarthritis. Arthritis Rheumatol. 2014;66:3317–26. CrossRef
Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur. J Pain. 2007;11:125–38.
Illingworth KD, El BY, Siewert K, Scaife SL, El-Amin S, Saleh KJ. Correlation of WOMAC and KOOS scores to tibiofemoral cartilage loss on plain radiography and 3 Tesla MRI: data from the osteoarthritis initiative. KneeSurgSports TraumatolArthrosc. 2014;22:1649–58.
Abhishek A, Doherty M. Understanding placebo effects in rheumatology. Jt Bone Spine. 2015;82:222–4. CrossRef
Shaygan M, Böger A, Kröner-Herwig B. Clinical features of chronic pain with neuropathic characteristics: a symptom-based assessment using the pain DETECT questionnaire. Eur J Pain. 2013;17:1529–38. PubMed
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–40. PubMed
EMA H, Dube B, Kingsbury SR, Tennant A, Conaghan PG. Toward a clinical definition of early osteoarthritis: onset of patient-reported knee pain begins on stairs. Data from the osteoarthritis initiative. Arthritis Care Res. 2015;67:40–7. CrossRef
Stratford PW, Kennedy DM, Woodhouse LJ, Spadoni GF. Measurement properties of the WOMAC LK 3.1 pain scale. Osteoarthr Cart. 2007;15:266–72. CrossRef
Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR, Riis BJ, et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthr Cartil. 2015;23
Karsdal MA, Bihlet A, Byrjalsen I, Alexandersen P, Ladel C, Michaels M, et al. OA phenotypes, rather than disease stage, drive structural progression - identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA. Osteoarthr Cartil. 2015;23
Hrobjartsson A. What are the main methodological problems in the estimation of placebo effects? J ClinEpidemiol. 2002;55:430–5.
Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMCMusculoskeletDisord. 2008;9:116.
Conaghan PG, Felson DT. Structural associations of osteoarthritis pain: lessons from magnetic resonance imaging. NovartisFoundSymp. 2004;260:191–201.
Graven-Nielsen T, Wodehouse T, Langford RM, rendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement 2012;64:2907–16.
Skou ST, Roos EM, Laursen MB. A randomized, controlled trial of Total knee replacement. NEnglJ Med. 2016;374:692. CrossRef
de Craen AJ, Kaptchuk TJ, Tijssen JG, Kleijnen J. Placebos and placebo effects in medicine: historical overview. J RSocMed. 1999;92:511–5.
Karsdal MA, Bihlet A, Byrjalsen I, Alexandersen P, Ladel C, Michaels M, et al. OA phenotypes, rather than disease stage, drive structural progression - identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA. Osteoarthr Cartil. 2015;23:550–8. CrossRefPubMed
Felson D, Niu J, Sack B, Aliabadi P, McCullough C, Nevitt MC. Progression Of osteoarthritis as a state of inertia. Ann Rheum Dis. 2012:1–6.
- Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis
Asger Reinstrup Bihlet
Jeppe Ragnar Andersen
Bente Juel Riis
Morten A. Karsdal
Marc C. Hochberg
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II